Key facts
- This page summarizes Alan List's Form 4 filing for PRECISION BIOSCIENCES INC (DTIL).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 May 2024, 18:30.
Alan List - 01 May 2024 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- DTIL
- Reported as of
- 01 May 2024
- Net transaction value
- -$2,993
- SEC form
- 4
- Accepted by SEC
- 03 May 2024, 18:30:23 UTC
- Prior SEC filing
- 30 Apr 2024
- Next SEC filing
- 22 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dario Scimeca, Attorney-in-Fact for Alan List
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alan List filed Form 4 for PRECISION BIOSCIENCES INC (DTIL) on 03 May 2024.
Change
- Previous filing in this sequence was filed on 30 Apr 2024.
- Current net transaction value: -$2,993.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DTIL
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +982
- Change %
- +26%
- Price
- Shares after
- 4,778
- Date
- 01 May 2024
- Ownership
- Direct
- Footnotes
- F1, F2
DTIL
transaction
Common Stock
Sale
- Transaction value
- $2,993
- Shares
- -290
- Change %
- -6.1%
- Price
- $10.32
- Shares after
- 4,488
- Date
- 02 May 2024
- Ownership
- Direct
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DTIL
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -982
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 981
- Date
- 01 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 982
- Exercise price
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents the partial vesting of Restricted Stock Units ("RSUs") on March 3, 2024, and subsequent settlement of such vested RSUs on May 1, 2024.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F3
The sales were effected pursuant to a Rule 10b5-1 plan adopted on March 24, 2022. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.53. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
Footnote F5
On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
SEC remarks
Exhibit Listing: Exhibit 24.1 Power of Attorney